|
Jun 30
|
Nektar Therapeutics Announces Proposed Public Offering
|
|
Jun 25
|
Why Nektar Therapeutics Stock Was Red-Hot Today
|
|
Jun 25
|
Wainwright sets over $100 target for Nektar on ‘paradigm-shifting’ data
|
|
Jun 25
|
NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study
|
|
Jun 24
|
Nektar Therapeutics Launches After Unearthing 'A New Biology' In Eczema Treatment
|
|
Jun 24
|
Sector Update: Health Care Stocks Advance Late Afternoon
|
|
Jun 24
|
Sector Update: Health Care Stocks Higher in Afternoon Trading
|
|
Jun 24
|
Nektar Therapeutics Stock Doubles After Promising Eczema Drug Trial Results
|
|
Jun 24
|
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?
|
|
Jun 24
|
REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis
|
|
Jun 23
|
Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025
|
|
Mar 14
|
Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)
|
|
Mar 14
|
Nektar Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Mar 13
|
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up
|
|
Mar 13
|
Q4 2024 Nektar Therapeutics Earnings Call
|
|
Mar 13
|
Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
|
|
Mar 13
|
Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say
|
|
Mar 12
|
Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates
|
|
Mar 12
|
Nektar: Q4 Earnings Snapshot
|
|
Mar 12
|
Assertio (ASRT) Reports Q4 Loss, Tops Revenue Estimates
|